


P3328

AN2728 Demonstrates Significant Safety and Efficacy in a Phase IIa Double Blind Trial in Plaque Type Psoriasis

K.R. Beutner, M. Toledo, L.T. Zane, A. Lathrop, D. Marti

Anacor Pharmaceuticals Inc., Palo Alto, CA, USA

Background



- AN2728 (5-(4-cyanophenoxy)-1,3-dihydro-1-hydroxy-2,1-benzoxaborole) is a novel broad spectrum anti-inflammatory compound that inhibits the release of TNF- α , IL-12, IL-23, and other cytokines
- AN2728 Ointment, 5% has demonstrated anti-psoriatic activity in two Phase Ib psoriasis plaque test trials

Study Objective

- To determine the safety and efficacy of AN2728 Ointment, 5% relative to vehicle in the treatment of plaque-type psoriasis

Study Design

Design:

- Treatment allocation: Randomized
- Blinding: Double (investigator, patient)
- Comparator/Control: Vehicle

Intervention:

- AN2728, 5% Ointment vs. Ointment vehicle (right vs. left, within patients)
- BID dosing x 4 weeks of treatment

Outcomes: assessed weekly

- Primary Endpoint: Overall Target Plaque Severity Score (OTPSS)
 - Range 0 (Clear) to 8 (Very severe)
- Scaling, Erythema, Plaque elevation


Population:

- 35 adults (≥ 18 yrs) with stable plaque-type psoriasis
 - Two comparable anatomically distinct lesions (OTPSS 2 “mild” to 4 “moderate”) on arms or trunk, separated by at least 10 cm


Primary Outcome: AN2728-Treated Plaques Superior in Greater Proportion of Patients

Analysis of the Overall Target Plaque Severity Score at Day 28 (Intent-to-Treat subjects):

<u>N</u>	<u>Percent of Subjects with Equal Severity</u>	<u>Percent of Subjects with Lesser Severity in AN2728</u>	<u>Percent of Subjects with Lesser Severity in Vehicle</u>	<u>Two-sided sign test p-value</u>
35	9 (25.7%)	24 (68.6%)	2 (5.7%)	<.001



AN2728 Superior in Greater Proportion of Plaques Beginning at Day 14




Two-Sided Sign Test:

* $P = 0.003$

** $P < 0.0001$

$n = 35$ in each group

AN2728 Superior to Vehicle in Overall Plaque Severity Score Beginning at Day 14




Paired t-test:

* $P < 0.001$


** $P < 0.0001$

AN2728 Superior to Vehicle in All Severity Parameters Beginning at Day 14




Scaling

†Day 14: $P = 0.005$



Plaque Elevation

†Day 14: $P = 0.018$



Erythema

†Day 14: $P = 0.003$

Paired t -test:

Other P values:

* $P < 0.001$

** $P < 0.0001$

No Treatment-Related Adverse Events Observed

- No treatment-related adverse events
 - One patient reported gingivitis and diarrhea
 - Severity graded as mild
 - Judged unrelated to study medication
 - No serious adverse events
- No cutaneous application site reactions
- No treatment-related laboratory abnormalities

Conclusion

- AN2728 Ointment, 5% applied twice daily for 4 weeks is well-tolerated and produces significant therapeutic benefit for plaque-type psoriasis